title: Effect of intraperitoneal administration of docetaxel on peritoneal dissemination of gastric cancer.
abstract: The effect of intraperitoneal (i.p.) administration of docetaxel was evaluated for preclinical evidence of anticancer activity in athymic mice bearing a gastric cancer cell line, MKN-45-P that shows a high rate of metastasis to the peritoneal cavity of nude mice. Nude mice were inoculated i.p. with 10(7) MKN-45-P cells. On days 2, 5, 9, 12, 16 and 19 after tumor inoculation, mice were treated with i.p. injection of docetaxel. Treatment doses of docetaxel were 8 mg/kg (N = 7) 2 mg/kg (N = 7) and 0.5 mg/kg (N = 7). Intraperitoneal carcinoembryonic antigen (CEA) levels, animal body weight, mortality and survival were determined. All control mice developed ascites and died within 19-40 days. The median survival time in the control group was 32 days, while those of mice treated with 8, 2 and 0.5 mg/kg were 90, 63 and 49.5 days, respectively. One of seven mice treated with 8 mg/kg of docetaxel died of toxicity on day 12. Four mice were tumor-free on day 90, but two had tumors in the abdomen when autopsied on day 90. One mouse treated with 2 mg/kg was ascertained to be tumor-free on day 90. All seven mice treated with 0.5 mg/kg of docetaxel died of peritoneal dissemination within 71 days. The results suggest the potential of intraperitoneal docetaxel administration for the treatment of peritoneal dissemination of gastric cancer.
authors.affiliation: Peritoneal Dissemination Program, Shizuoka Cancer Center, 1007 Shimo-nagakubo, Nagaizumi-machi, Suntou-gun, Shizuoka 411-8777, Japan. y.yonemura@scchr.jp
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Yonemura
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Endou
authors.forename: Etsurou
authors.initials: E
authors.lastname: Bando
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Kuno
authors.forename: Taiichi
authors.initials: T
authors.lastname: Kawamura
authors.forename: Masashi
authors.initials: M
authors.lastname: Kimura
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Shimada
authors.forename: Ken-Ichi
authors.initials: K
authors.lastname: Miyamoto
authors.forename: Takuma
authors.initials: T
authors.lastname: Sasaki
authors.forename: Paul H
authors.initials: PH
authors.lastname: Sugarbaker
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000494:pharmacology*; D002272:Carcinoembryonic Antigen / Q000032:analysis; D000077143:Docetaxel; D005260:Female; D007263:Infusions, Parenteral; D051379:Mice; D008819:Mice, Nude; D009374:Neoplasms, Experimental; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000556:secondary* / Q000662:veterinary; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016019:Survival Analysis; D043823:Taxoids / Q000008:administration & dosage* / Q000494:pharmacology*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D002272:Carcinoembryonic Antigen; D043823:Taxoids; D000077143:Docetaxel